Murine Model of Gammaherpesvirus Latency

伽马疱疹病毒潜伏期小鼠模型

基本信息

  • 批准号:
    6514926
  • 负责人:
  • 金额:
    $ 26.19万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2001
  • 资助国家:
    美国
  • 起止时间:
    2001-07-01 至 2006-06-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The long-term objective of the proposed research is to define the mechanisms that enable the gamma herpesviruses to persist indefinitely within their immunocompetent hosts. These mechanisms underlie the pathogenesis and oncogenic potential associated with these viruses, particularly in individuals with acquired or inherited immunodeficiencies. Unfortunately, due to the extreme host restrictions of the human gamma-herpesviruses Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV), it has not been possible to directly address the mechanisms responsible for EBV and KSHV persistence in a relevant host setting. Infection of laboratory mice with the murine gamma-herpesvirus MHV-68 (closely related to KSHV) offers a highly tractable and potential model of human gamma-herpesvirus persistence, but viral latency in this system has not been sufficiently characterized at the molecular level to enable exploitation of this model for these purposes. Therefore, the immediate goals of the proposed research are to define the molecular characteristics of MHV-68 latency. To obtain our objective, we propose three specific aims. Under Aim 1 we will define the programs of MHV-68 latency gene expression during the establishment and maintenance phases of latency within the hematopoietic-cell reservoirs of latent virus (activated and resting B cells, macrophages, and dendritic cells). Specifically, we will screen these cells by RT-PCR and Southern blot hybridization for expression of the MHV-68 latency genes M2, M3, M1 1, 72, 73 and 74. Additionally, we propose to identify potentially novel MHV-68 latency genes expressed in these cells that are not apparent from analysis of the viral genornic DNA sequence. Under Aim 2 we will address the functions of three latency-associated genes: M2, 73 and 74, for which little or no information is available. Under Aim 3 we will define the impact of MHV-68 latency on cellular gene expression in vivo at the cellular level. Together, these specific aims will fill the significant gaps that currently remain in our knowledge of the latent life cycle of MHV-68, as well as provide better insight into the mechanisms that the gamma-herpesviruses as a group exploit to maintain latency, and thus contribute to their pathogenic potential.
描述(由申请人提供):建议的长期目标

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JEFFERY T SAMPLE其他文献

JEFFERY T SAMPLE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JEFFERY T SAMPLE', 18)}}的其他基金

Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
  • 批准号:
    8806522
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
  • 批准号:
    8659714
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
Viral Long Noncoding RNA Functions in Epstein-Barr Virus Infection
病毒长非编码 RNA 在 Epstein-Barr 病毒感染中的功能
  • 批准号:
    9017925
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
Mechanisms of Epstein-Barr Virus Persistence
EB 病毒持续存在的机制
  • 批准号:
    8728373
  • 财政年份:
    2013
  • 资助金额:
    $ 26.19万
  • 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
  • 批准号:
    7621316
  • 财政年份:
    2009
  • 资助金额:
    $ 26.19万
  • 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
  • 批准号:
    7847575
  • 财政年份:
    2009
  • 资助金额:
    $ 26.19万
  • 项目类别:
Mechanisms of Gene Regulation by EBV EBNA-1 Protein
EBV EBNA-1蛋白的基因调控机制
  • 批准号:
    7681398
  • 财政年份:
    2008
  • 资助金额:
    $ 26.19万
  • 项目类别:
Small Molecule Inhibitors of EBV Latency
EBV潜伏期的小分子抑制剂
  • 批准号:
    6656740
  • 财政年份:
    2003
  • 资助金额:
    $ 26.19万
  • 项目类别:
Small Molecule Inhibitors of EBV Latency
EBV潜伏期的小分子抑制剂
  • 批准号:
    6719551
  • 财政年份:
    2003
  • 资助金额:
    $ 26.19万
  • 项目类别:
Murine Model of Gammaherpesvirus Latency
伽马疱疹病毒潜伏期小鼠模型
  • 批准号:
    6633947
  • 财政年份:
    2001
  • 资助金额:
    $ 26.19万
  • 项目类别:

相似海外基金

GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
  • 批准号:
    8653055
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
The role of activation-induced cytidine deaminase (AID) mediated DNA damage in the pathogenesis of Burkitt's Lymphoma
活化诱导胞苷脱氨酶 (AID) 介导的 DNA 损伤在伯基特淋巴瘤发病机制中的作用
  • 批准号:
    258438392
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
    Research Fellowships
GSK3 inhibition as an adjuvant therapy for Burkitt's lymphoma
GSK3 抑制作为伯基特淋巴瘤的辅助治疗
  • 批准号:
    8788701
  • 财政年份:
    2014
  • 资助金额:
    $ 26.19万
  • 项目类别:
The interaction of Burkitt's lymphoma cofactors EBV and Plasmodium
伯基特淋巴瘤辅助因子 EBV 和疟原虫的相互作用
  • 批准号:
    8846480
  • 财政年份:
    2012
  • 资助金额:
    $ 26.19万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7289830
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7097879
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
REGULATION OF EBV TRANSCRIPTION IN BURKITT'S LYMPHOMA
伯基特淋巴瘤中 EBV 转录的调控
  • 批准号:
    7349162
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7684750
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7492826
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
Targeting of EBV Latency in Burkitt's Lymphoma
伯基特淋巴瘤中 EBV 潜伏期的靶向治疗
  • 批准号:
    7935180
  • 财政年份:
    2006
  • 资助金额:
    $ 26.19万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了